NeoStem Receives SFDA Approval for Proton Pump Inhibitor
publication date: Jan 25, 2010
NeoStem, Inc. said its China subsidiary, Suzhou Erye Pharmaceutical, was granted SFDA approval for omeprazole 20mg capsules. Omeprazole is a proton pump inhibitor prescribed to treat peptic ulcer disease and gastroesophageal reflux disease. The drug is on China's National Medical Reimbursement Insurance List, making it eligible for insurance reimbursement. More details...
Stock Symbol: (NYSE Amex: NBS)